Mustang Bio, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

License, Clinical Trial and Sponsored Research Agreements (Tables)

12 Months Ended

Dec. 31, 2018

License Agreement Disclosure [Abstract]

Research and Development Arrangement, Contract to Perform for Others [Table Text Block]

For the years ended December 31, 2018 and 2017, the Company recorded the following expense in research and development for licenses acquired:

	For the year ended December 31,
($ in thousands)	2018		2017
City of Hope
Manufacturing	$	75	$	-
IL13Rα2		-		500
IV/ICV		-		125
PSCA		-		300
HER2		200		600
CS1		-		600
Harvard University - CRISPR		-		250
UCLA		-		200
Fred Hutch - CD20		-		300
St. Jude - XSCID		1,000		-
Fortress PIK Dividend		2,085		9,558
Total	$	3,360	$	12,433

For the years ended December 31, 2018 and, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:

	For the year ended December 31,
	2018		2017
($ in thousands)
City of Hope	$	2,000	$	2,000
City of Hope - CD123		835		1,227
City of Hope - IL13Rα2		1,056		1,578
City of Hope - Manufacturing		458		-
Fred Hutch - CD20		1,301		614
BIDMC - CRISPR		69		138
Total	$	5,719	$	5,557